# Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

> **NCT03314662** · PHASE3 · COMPLETED · sponsor: **Seqirus** · enrollment: 1778 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)
- **BIOLOGICAL:** Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1)
- **BIOLOGICAL:** MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)

## Key facts

- **NCT ID:** NCT03314662
- **Lead sponsor:** Seqirus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-17
- **Primary completion:** 2017-12-11
- **Final completion:** 2018-05-17
- **Target enrollment:** 1778 (ACTUAL)
- **Last updated:** 2020-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03314662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03314662, "Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03314662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*